Tilray Brands, Inc. (TLRY, Financial) shares experienced a significant rise of 5.06%, with the price reaching $1.77 per share. The trading volume was 16.65 million shares with a turnover rate of 1.90% and a price fluctuation of 5.36%.
Recent financial reports reveal that Tilray's revenue stands at $789 million, with a net loss of $245 million and earnings per share at -$0.33. The company's gross profit is $139 million, resulting in a PE ratio of -5.29. Among 13 rating institutions, 23% recommend buying while 77% suggest holding, with no sell recommendations.
The pharmaceutical sector, in which Tilray operates, experienced an overall decline of 0.79%. Within this sector, Eton Pharmaceuticals, Inc., Harrow, Inc., and Biofrontera Inc. saw significant gains. Stocks like SuXuanTang, Biofrontera Inc., and Canopy Growth Corporation showed notable activity with turnover rates of 8.03%, 5.11%, and 3.19%, respectively. Stocks with substantial price fluctuations included Eagle Pharmaceuticals, Citius Oncology, Inc., and Eton Pharmaceuticals, Inc., with volatility rates of 21.03%, 15.03%, and 12.88% respectively.
Tilray is a Canadian producer of cannabis for medical and recreational use. The company became Tilray Brands following a reverse acquisition of legacy Tilray by legacy Aphria in 2021. Its primary market is Canada and the international medical cannabis export market, with U.S. products including CBD and alcoholic beverages.
